Matthew  Lang net worth and biography

Matthew Lang Biography and Net Worth

General Counsel of Myovant Sciences
Mr. Lang has served as our General Counsel since July 2017 and as our Corporate Secretary since September 2018. Mr. Lang also currently serves as the Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. and is the General Manager of Myovant Sciences GmbH based in Basel, Switzerland. Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc., a biopharmaceutical company, where he worked from November 2009 to July 2017. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team and the Global Compliance Committee. Prior to Gilead, from 2003 to 2009, Mr. Lang was an attorney at Dechert LLP in New York City, where he represented companies and executives in regulatory enforcement matters, internal investigations, criminal defense matters, labor disputes, and other civil litigation and appeals. Mr. Lang served as a member of the board of directors of the United Way Bay Area from 2015 to 2018. Mr. Lang received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.

What is Matthew Lang's net worth?

The estimated net worth of Matthew Lang is at least $9.56 million as of January 18th, 2023. Mr. Lang owns 354,303 shares of Myovant Sciences stock worth more than $9,559,095 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Lang may own. Learn More about Matthew Lang's net worth.

How do I contact Matthew Lang?

The corporate mailing address for Mr. Lang and other Myovant Sciences executives is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. Myovant Sciences can also be reached via phone at 442074003351 and via email at [email protected]. Learn More on Matthew Lang's contact information.

Has Matthew Lang been buying or selling shares of Myovant Sciences?

Matthew Lang has not been actively trading shares of Myovant Sciences in the last ninety days. Most recently, Matthew Lang sold 1,272 shares of the business's stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $26.89, for a transaction totalling $34,204.08. Following the completion of the sale, the general counsel now directly owns 354,303 shares of the company's stock, valued at $9,527,207.67. Learn More on Matthew Lang's trading history.

Who are Myovant Sciences' active insiders?

Myovant Sciences' insider roster includes Juan Arjona Ferreira (Insider), Matthew Lang (General Counsel), and David Marek (Insider). Learn More on Myovant Sciences' active insiders.

Matthew Lang Insider Trading History at Myovant Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2023Sell1,272$26.89$34,204.08354,303View SEC Filing Icon  
1/4/2023Sell2,779$26.90$74,755.10355,575View SEC Filing Icon  
10/18/2022Sell1,933$25.20$48,711.60358,354View SEC Filing Icon  
10/4/2022Sell3,679$24.40$89,767.60360,287View SEC Filing Icon  
8/15/2022Sell31,214$18.23$569,031.22363,966View SEC Filing Icon  
7/18/2022Sell1,935$12.87$24,903.45270,400View SEC Filing Icon  
7/6/2022Sell3,702$13.40$49,606.80272,335View SEC Filing Icon  
4/19/2022Sell8,002$10.45$83,620.90276,037View SEC Filing Icon  
4/5/2022Sell2,436$13.78$33,568.08View SEC Filing Icon  
1/4/2022Sell4,475$16.27$72,808.25View SEC Filing Icon  
10/5/2021Sell6,671$21.62$144,227.02View SEC Filing Icon  
7/9/2021Sell6,954$21.52$149,650.08186,510View SEC Filing Icon  
4/6/2021Sell10,862$18.62$202,250.44135,003View SEC Filing Icon  
3/15/2021Sell30,000$25.07$752,100.00175,865View SEC Filing Icon  
12/18/2020Sell10,000$25.41$254,100.00155,865View SEC Filing Icon  
12/10/2020Sell19,400$25.20$488,880.00146,465View SEC Filing Icon  
8/31/2020Sell26,700$20.05$535,335.00172,565View SEC Filing Icon  
8/28/2020Sell2,700$20.02$54,054.00145,965View SEC Filing Icon  
8/26/2020Sell100$20.00$2,000.00145,965View SEC Filing Icon  
8/19/2020Sell600$20.00$12,000.00146,465View SEC Filing Icon  
12/30/2019Sell19,018$15.55$295,729.9034,597View SEC Filing Icon  
See Full Table

Matthew Lang Buying and Selling Activity at Myovant Sciences

This chart shows Matthew Lang's buying and selling at Myovant Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Myovant Sciences Company Overview

Myovant Sciences logo
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $26.98
Low: $26.98
High: $27.00

50 Day Range

MA: $26.96
Low: $26.88
High: $26.99

2 Week Range

Now: $26.98
Low: $7.67
High: $27.06

Volume

2,256,078 shs

Average Volume

1,169,678 shs

Market Capitalization

$2.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17